Indivior’s Supernus Merger Pairs a $1 Billion Payout With a New Debt Load

RICHMOND, Va., September 11, 2026

Indivior Pharmaceuticals has put the full economics of its Supernus combination in front of investors, turning a broadly pitched merger of equals into a more pointed capital-allocation decision. Holders are being asked to exchange Indivior’s concentrated addiction-treatment story for a larger CNS portfolio, a new management team and $1 billion in cash before closing. The price of that payout is a meaningfully more levered balance sheet.

The definitive joint proxy statement and prospectus filed Friday advances the transaction toward shareholder votes. This is an issuance tied to a business combination, not a marketed IPO with a price range or an underwriting syndicate. Supernus holders would receive 1.5401 Indivior shares for each Supernus share, while existing Indivior holders would own about 56.5% of the combined company and Supernus holders about 43.5% on a fully diluted basis.

The dividend defines the deal

Immediately before closing, Indivior plans to pay its pre-close shareholders a $1 billion special dividend. A joint transaction announcement says Citibank has committed a $650 million term loan for the distribution, with the balance funded from the combined companies’ cash. Management presents pro forma net debt of roughly $878 million and net leverage below 1 times adjusted EBITDA, but that leverage calculation includes the full $125 million of anticipated annual cost synergies and excludes transaction costs, financing fees and the costs needed to capture those savings.

IPOGrid reads the dividend as the central negotiation between the two shareholder groups. It delivers cash directly to Indivior holders while preserving their majority ownership, but the resulting company inherits the borrowing and integration burden. Supernus shareholders bring a net-cash balance sheet into the combination and receive minority ownership in an issuer that will adopt their company’s name, Rockville headquarters, chief executive and Nasdaq ticker, SUPN.

The governance split is nominally even: four directors from each side on an eight-member board. Supernus CEO Jack Khattar would lead the combined company, and Indivior director Tony Kingsley would become chair. Indivior CEO Joe Ciaffoni is not slated to run the business after closing. That makes the deal’s economics more revealing than its “merger of equals” label. Our interpretation is that Indivior shareholders retain the larger equity stake and collect the cash, while Supernus supplies the continuing corporate identity and operating leadership.

Operating momentum gives the financing room

Indivior enters the vote with a substantially stronger earnings profile than it showed a year ago. In its second-quarter results, revenue rose 14% to $343 million, SUBLOCADE revenue increased 21% to $253 million and adjusted EBITDA more than doubled to $186 million. For the first half, revenue reached $660 million and adjusted EBITDA was $350 million. The company also raised 2026 guidance to $1.295 billion to $1.365 billion of revenue and $700 million to $740 million of adjusted EBITDA.

Those figures help explain why the proposed borrowing can screen as moderate after synergies. They also expose concentration risk. SUBLOCADE supplied nearly three quarters of Indivior’s second-quarter revenue, by our calculation from the reported figures. Supernus brings products across ADHD, Parkinson’s disease, postpartum depression and epilepsy, giving the combined company 11 commercial medicines across addiction, psychiatry and neurology.

The companies cite approximately $2.2 billion of trailing combined revenue and $888 million of pro forma adjusted EBITDA, including synergies. The reviewer’s concern is that $125 million of annual savings does considerable work in that headline. It represents about 14% of the stated pro forma EBITDA and is expected to arrive only after integration. Until then, investors are underwriting execution across two sales organizations and product portfolios while the new term loan begins to shape cash allocation.

Forecasts rise, but so does the burden of proof

The definitive prospectus includes Indivior management forecasts of $1.32 billion in 2026 revenue, $1.394 billion in 2027 and $1.523 billion in 2028, with adjusted EBITDA of $680 million, $774 million and $870 million, respectively. Those are transaction projections, not guidance promises. The 2026 EBITDA forecast also sits below the company’s subsequently raised public guidance range, a reminder that merger models are built at a point in time and should not be treated as a fresh earnings outlook.

The deal is targeted to close in the fourth quarter, subject to both shareholder approvals, regulatory clearance, effectiveness of the share registration and Nasdaq approval for the new shares. The merger agreement disclosure also shows asymmetric walk-away costs: Indivior could owe Supernus $174 million in specified circumstances, while Supernus could owe Indivior $101 million.

For public-market investors, Friday’s prospectus does not settle whether diversification merits the added debt. It makes the choice legible. Indivior is contributing the faster near-term profit engine, its holders receive the cash extraction, and Supernus takes the managerial wheel. If the $125 million synergy plan lands on schedule, the balance sheet should remain manageable. If integration slips or product growth softens, the special dividend will look less like surplus capital and more like leverage the renamed company must work off.